Hunan Huateng Pharmaceutical Co. Ltd. articles

Huateng Pharma, a leading Contract Development and Manufacturing Organization (CDMO), is proud to announce the launch of its latest product, Piroctone Olamine (CAS: 68890-66-4). This addition underscores Huateng Pharma’s commitment to providing high-quality pharmaceutical ingredients to meet the diverse needs of the global health and personal care industries.

Piroctone Olamine is a highly effective antifungal

Huateng Pharma, a leading supplier of high-quality ingredients for the pharmaceutical and cosmetic industries, is proud to announce its range of novel ingredients designed for both commodities and cosmetics. The company is committed to delivering excellence from lab to commercial scale, ensuring the highest standards of quality and performance.

1. Tetrahydrocurcumin (CAS No. 36062-04-1): Antioxidant and Skin-Whitening Powerhouse

Huateng Pharma introduces

Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral drug for the treatment of refractory hypertension in the 1970s. In later clinical applications, doctors observed hair regrowth and generalized excessive hair in balding patients, which led to the development of minoxidil preparations.

Minoxidil can increase local blood supply, stimulate the proliferation and differentiation of hair follicle epithelial cells, so as to promote hair growth

Diabetes is a chronic disease that affects more than 540 million people worldwide and is one of the leading causes of death and disability worldwide. In China, there are more than 114 million adults with diabetes, accounting for about a quarter of the world's diabetes patients. With the change of living and eating habits, diabetes has become the third major factor affecting human health after cardiovascular and cerebrovascular diseases and malignant tumors, bringing a heavy physical and menta

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer – that is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally.

The majority of patients with metastatic breast cancer (

According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.

Although more drug choices such as pertuzumab a

Metformin is a classic first-line hypoglycemic agent for patients with type 2 diabetes, and is an essential drug in combination regimenes. However, as the evidence is updated, the idea of drug selection for first-line treatment is changing. GLP-1 agonists and SGLT-2 inhibitors in combination with or without metformin (as required for glycemic management) have also been recommended by multiple guidelines as appropriate initial treatment for type 2 diabetes patients with atherosclerotic cardiov

Targeted protein degradation (TPD) is a promising strategy in the field of drug discovery. In recent years, targeted protein degradation (TPD) technology has developed rapidly, especially proteolysis targeting chimera (PROTAC), which is the most representative technology of TPD strategy. TPD drugs are one of the hot spots of new drug development in recent years, especially in the field of oncology. For example, a TPD drug developed by Arvinas has achieved proof-of-concept in clinica

Tetrahydrocurcumin (THC), as the most active and main metabolite produced in the metabolism of curcumin in vivo, can be isolated from the cytoplasm of the small intestine and liver after curcumin administration in human or mouse. Tetrahydrocurcumin can effectively inhibit tyrosinase, inhibit the generation of Oxygen Free Radicals and scavenge the formed free radicals. It has obvious antioxidant effect and has been used as a natural functional whitening raw material for cosmetics research and

Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently being looked at as optimal antigens, which have been shown to be targeted by ADCs.